Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03500731 · ClinicalTrials.gov registry record · Phase 1
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
A Phase 1 study of Idiopathic Pulmonary Fibrosis and Emphysema or COPD, sponsored by Paul Szabolcs.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 2
- Study locations
NCT03500731: Recruiting Phase 1 study of Idiopathic Pulmonary Fibrosis and Emphysema or COPD, sponsored by Paul Szabolcs.
NCT03500731 is a Phase 1 study of Idiopathic Pulmonary Fibrosis and Emphysema or COPD that is actively recruiting participants, run by Paul Szabolcs. The registered enrollment target is 8 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03500731, a Phase 1 study of Idiopathic Pulmonary Fibrosis and Emphysema or COPD, is actively recruiting participants, sponsored by Paul Szabolcs.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
Primary Outcome
How many, if any, patients die
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Alemtuzumab
- DRUG Rituximab
- DRUG Thiotepa
- BIOLOGICAL CD3/CD19 negative hematopoietic stem cells
Study Locations (2)
Pennsylvania
- UPMC Presbyterian - Pittsburgh
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-04-19 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT03500731 shows while recruiting
NCT03500731 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT03500731 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03500731 about?
NCT03500731 is a clinical study titled "Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure". The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
What is the current status of trial NCT03500731?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-04-19. Estimated completion is 2028-12.
What conditions does trial NCT03500731 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Emphysema or COPD.
What interventions are being tested in trial NCT03500731?
The interventions under investigation include: Fludarabine (DRUG), Alemtuzumab (DRUG), Rituximab (DRUG), Thiotepa (DRUG), CD3/CD19 negative hematopoietic stem cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03500731?
This trial is sponsored by Paul Szabolcs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03500731 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03500731's enrollment target sits among peer trials
8 51st of 51 higher than 1 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose-Escalation Study of Artesunate Patients With IPF
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
NAL ER IPF Respiratory Function and Safety Study
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
ACTIVE NOT RECRUITING · Phase 1
-
Atezolizumab for Idiopathic Pulmonary Fibrosis
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI